ID   CLF_PEDS0005_N
AC   CVCL_C9B2
DR   dbGAP; phs001800.v1.p1
DR   Wikidata; Q123030935
RX   PubMed=30860482;
CC   Population: African American.
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C9B3 ! CLF_PEDS0005_T1
OI   CVCL_C9B4 ! CLF_PEDS0005_T2A
OI   CVCL_C9B5 ! CLF_PEDS0005_T2B
CA   Finite cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=30860482; DOI=10.7554/eLife.44161; PMCID=PMC6436895;
RA   Hong A.L., Tseng Y.-Y., Wala J.A., Kim W.-J., Kynnap B.D., Doshi M.B.,
RA   Kugener G., Sandoval G.J., Howard T.P., Li J., Yang X.-P., Tillgren M.,
RA   Ghandi M., Sayeed A., Deasy R., Ward A., McSteen B., Labella K.M.,
RA   Keskula P., Tracy A., Connor C., Clinton C.M., Church A.J.,
RA   Crompton B.D., Janeway K.A., Van Hare B., Sandak D., Gjoerup O.V.,
RA   Bandopadhayay P., Clemons P.A., Schreiber S.L., Root D.E.,
RA   Gokhale P.C., Chi S.N., Mullen E.A., Roberts C.W.M., Kadoch C.,
RA   Beroukhim R., Ligon K.L., Boehm J.S., Hahn W.C.;
RT   "Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive
RT   to proteasome inhibition.";
RL   eLife 8:e44161.1-e44161.32(2019).
//